Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ

Clinical Proteomics

Karin Sundfeldt¹  Elisabet Carlsohn²  Karolina Partheen¹  Kristina Levan¹  Björg Kristjansdottir¹ 

[1] Institute of Clinical Sciences, Department of Obstetrics and Gynecology, University of Gothenburg, Gothenburg S-413 45, Sweden;Proteomics Core Facility at Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

关键词: iTRAQ;    Mass spectrometry;    Tumor biomarker;    Ovarian cyst fluid;    Ovarian adenocarcinoma;   

Others  :  1026346
DOI  :  10.1186/1559-0275-10-4

 received in 2012-08-04, accepted in 2013-03-14,  发布年份 2013

【 摘 要 】

Background

Epithelial-derived ovarian adenocarcinoma (EOC) is the most deadly gynecologic tumor, and the principle cause of the poor survival rate is diagnosis at a late stage. Screening and diagnostic biomarkers with acceptable specificity and sensitivity are lacking. Ovarian cyst fluid should harbor early ovarian cancer biomarkers because of its closeness to the tumor. We investigated ovarian cyst fluid as a source for discovering biomarkers for use in the diagnosis of EOC.

Results

Using quantitative mass spectrometry, iTRAQ MS, we identified 837 proteins in cyst fluid from benign, EOC stage I, and EOC stage III. Only patients of serous histology were included in the study. Comparing the benign (n = 5) with the malignant (n = 10) group, 87 of the proteins were significantly (p < 0.05) differentially expressed. Two proteins, serum amyloid A-4 (SAA4) and astacin-like metalloendopeptidase (ASTL), were selected for verification of the iTRAQ method and external validation with immunoblot in a larger cohort with mixed histology, in plasma (n = 68), and cyst fluid (n = 68). The protein selections were based on either high significance and high fold change or abundant appearance and several peptide recognitions in the sample sets (p = 0.04, FC = 1.95) and (p < 0.001, FC = 8.48) for SAA4 and ASTL respectively. Both were found to be significantly expressed (p < 0.05), but the methods did not correlate concerning ASTL.

Conclusions

Fluid from ovarian cysts connected directly to the primary tumor harbor many possible new tumor-specific biomarkers. We have identified 87 differentially expressed proteins and validated two candidates to verify the iTRAQ method. However several of the proteins are of interest for validation in a larger setting.

【 授权许可】

   
2013 Kristjansdottir et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Socialstyrelsen CfEoTSNBoHaW: Causes of death 2008. The Swedish National Board of Health and Welfare; 2010. www.socialstyrelsen.se/statistik/statistikefteramne/cancer webcite
• [2]Kristjansdottir B, Partheen K, Fung ET, Marcickiewicz J, Yip C, Brannstrom M, Sundfeldt K: Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers. Clinical Proteomics 2012, 9(1):14. BioMed Central Full Text
• [3]Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S161-S192.
• [4]van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ: Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 2007, 109(9):1887-1896.
• [5]MacDonald ND, Jacobs IJ: Is there a place for screening in ovarian cancer? Eur J Obstet Gynecol Reprod Biol 1999, 82(2):155-157.
• [6]Shih Ie M, Kurman RJ: Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res: An Official J Am Assoc Cancer Res 2005, 11(20):7273-7279.
• [7]Markman M: The role of CA-125 in the management of ovarian cancer. Oncologist 1997, 2(1):6-9.
• [8]Markman M, Federico M, Liu PY, Hannigan E, Alberts D: Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol 2006, 103(1):195-198.
• [9]Meyer T, Rustin GJ: Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000, 82(9):1535-1538.
• [10]Kolwijck E, Span PN, Thomas CM, Bulten J, Sweep FC, Massuger LF: Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer. Oncol Rep 2010, 23(2):579-584.
• [11]Kolwijck E, Zusterzeel PL, Roelofs HM, Hendriks JC, Peters WH, Massuger LF: GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2009, 18(8):2176-2181.
• [12]Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC: Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993, 85(21):1748-1751.
• [13]Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A: Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010, 117(3):440-445.
• [14]Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108(2):402-408.
• [15]Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63(13):3695-3700.
• [16]Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ, Berchuck A: Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008, 110(3):374-382.
• [17]Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C: Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand 2009, 88(1):18-26.
• [18]Ivarsson K, Runesson E, Sundfeldt K, Haeger M, Hedin L, Janson PO, Brannstrom M: The chemotactic cytokine interleukin-8–a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncol 1998, 71(3):420-423.
• [19]Sundfeldt K, Ivarsson K, Rask K, Haeger M, Hedin L, Brannstrom M: Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts. Anticancer Res 2001, 21(1A):65-70.
• [20]Boylan KL, Andersen JD, Anderson LB, Higgins L, Skubitz AP: Quantitative proteomic analysis by iTRAQ(R) for the identification of candidate biomarkers in ovarian cancer serum. Proteome Sci 2010, 8:31. BioMed Central Full Text
• [21]Gagne JP, Ethier C, Gagne P, Mercier G, Bonicalzi ME, Mes-Masson AM, Droit A, Winstall E, Isabelle M, Poirier GG: Comparative proteome analysis of human epithelial ovarian cancer. Proteome science 2007, 5:16. BioMed Central Full Text
• [22]Waldemarson S, Krogh M, Alaiya A, Kirik U, Schedvins K, Auer G, Hansson KM, Ossola R, Aebersold R, Lee H: Protein expression changes in ovarian cancer during the transition from benign to malignant. J Proteome Res 2012, 11(5):2876-2889.
• [23]Ryu JK, Woo SM, Hwang JH, Jeong JB, Yoon YB, Park IA, Han JK, Kim YT: Cyst fluid analysis for the differential diagnosis of pancreatic cysts. Diagn Cytopathol 2004, 31(2):100-105.
• [24]Toyama A, Suzuki A, Shimada T, Aoki C, Aoki Y, Umino Y, Nakamura Y, Aoki D, Sato TA: Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers. Cancer Sci 2012, 103(4):747-755.
• [25]Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke RP, Levin M, Urieli-Shoval S: Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. The J histochemistry and Cytochemistry: Official J Histochemistry Soc 2006, 54(1):63-73.
• [26]Michaeli A, Finci-Yeheskel Z, Dishon S, Linke RP, Levin M, Urieli-Shoval S: Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer. Biochem Biophys Res Commun 2008, 368(2):368-373.
• [27]Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D: Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. The J Histochemistry and Cytochemistry: Official J Histochemistry Soc 2010, 58(11):1015-1023.
• [28]Quesada V, Sanchez LM, Alvarez J, Lopez-Otin C: Identification and characterization of human and mouse ovastacin: a novel metalloproteinase similar to hatching enzymes from arthropods, birds, amphibians, and fish. J Biol Chem 2004, 279(25):26627-26634.
• [29]Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009, 115(1):112-120.
• [30]Cohen M, Petignat P: Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells. Cancer Lett 2011, 309(1):104-109.
• [31]Jakobsen CG, Rasmussen N, Laenkholm AV, Ditzel HJ: Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78. Cancer Res 2007, 67(19):9507-9517.
• [32]Kim Y, Lillo AM, Steiniger SC, Liu Y, Ballatore C, Anichini A, Mortarini R, Kaufmann GF, Zhou B, Felding-Habermann B: Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry 2006, 45(31):9434-9444.
• [33]Parker D, Bradley C, Bogle SM, Lay J, Masood M, Hancock AK, Naylor B, Price JJ: Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994, 101(10):888-893.
• [34]McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001, 41(1–2):64-69.
• [35]Cortesi L, Rossi E, Della Casa L, Barchetti A, Nicoli A, Piana S, Abrate M, La Sala GB, Federico M, Iannone A: Protein expression patterns associated with advanced stage ovarian cancer. Electrophoresis 2011, 32(15):1992-2003.
• [36]Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, Lee HP: Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res 2009, 18(2–3):47-56.
• [37]Kim HJ, Kang HJ, Lee H, Lee ST, Yu MH, Kim H, Lee C: Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res 2009, 8(3):1368-1379.
• [38]Ott HW, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A, Fessler S, Schwaerzler P, Zeimet A, Marth C: Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 2003, 63(21):7507-7514.
• [39]Kostakis ID, Cholidou KG, Kallianidis K, Perrea D, Antsaklis A: The role of calprotectin in obstetrics and gynecology. Eur J Obstet Gynecol Reprod Biol 2010, 151(1):3-9.
• [40]Esposito I, Kayed H, Keleg S, Giese T, Sage EH, Schirmacher P, Friess H, Kleeff J: Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia 2007, 9(1):8-17.
• [41]Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y, Zheng S: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol 2011, 17(15):2028-2036.
• [42]Hogdall C, Fung ET, Christensen IJ, Nedergaard L, Engelholm SA, Petri AL, Risum S, Lundvall L, Yip C, Pedersen AT: A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol 2011, 123(2):308-313.
• [43]Maines-Bandiera S, Woo MM, Borugian M, Molday LL, Hii T, Gilks B, Leung PC, Molday RS, Auersperg N: Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer. Int J Gynecol Cancer 2010, 20(1):16-22.
• [44]Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage EH, O’Dwyer PJ, Livolsi VA, Johnson SW: Gene expression profiling of human ovarian tumours. Br J Cancer 2006, 95(8):1092-1100.
• [45]Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN: HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 2010, 11(1):111-116.
• [46]Carlsohn E, Nystrom J, Karlsson H, Svennerholm AM, Nilsson CL: Characterization of the outer membrane protein profile from disease-related Helicobacter pylori isolates by subcellular fractionation and nano-LC FT-ICR MS analysis. J Proteome Res 2006, 5(11):3197-3204.
• [47]Zhu Y, Brannstrom M, Janson PO, Sundfeldt K: Differences in expression patterns of the tight junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer J Int Du Cancer 2006, 118(8):1884-1891.